Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203433 | 0.82 | PRMT5 (0.40) | TLR7ADORA2AADORA3ADORA1TLR8 | |
| SCHEMBL202918 | 0.75 | TLR7 (0.46) | TLR7ADORA2ALMNAPOLBHRH2 | |
| SCHEMBL203256 | 0.75 | KDM5B (0.43) | ADORA3KDM5B | |
| SCHEMBL4753594 | 0.68 | TLR7 (0.59) | TLR7ADORA2ALMNAPOLBHRH2 | |
| SCHEMBL3183969 | 0.67 | TLR7 (0.62) | TLR7ADORA2ALMNAPOLBHRH2 | |
| SCHEMBL6030934 | 0.67 | TLR7 (0.59) | TLR7ADORA2ALMNAPOLBHRH2 | |
| SCHEMBL4758352 | 0.67 | TLR7 (0.49) | TLR7ADORA2ALMNAPOLBHRH2 | |
| SCHEMBL3178360 | 0.67 | TLR7 (0.63) | TLR7ADORA2ALMNAPOLBHRH2 | |
| SCHEMBL4754153 | 0.67 | TLR7 (0.52) | TLR7ADORA2ALMNAPOLBHRH2 | |
| SCHEMBL29694218 | 0.66 | TLR7 (0.44) | TLR7ADORA2ALMNAPOLBHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | TLR7 69/4885ADORA2A 1608/4885LMNA 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.